keyword
MENU ▼
Read by QxMD icon Read
search

high risk prostate cancer

keyword
https://www.readbyqxmd.com/read/28229097/pediatric-hypovitaminosis-d-molecular-perspectives-and-clinical-implications
#1
Rafiu Ariganjoye
Vitamin D, a secosteroid, is essential for the development and maintenance of healthy bone in both the adult and pediatric populations. Low level of 25-hydroxy vitamin D (25-(OH)-D) is highly prevalent in children worldwide and has been linked to various adverse health outcomes including rickets, osteomalacia, osteomalacic myopathy, sarcopenia, and weakness, growth retardation, hypocalcemia, seizure and tetany, autism, cardiovascular diseases, diabetes mellitus, cancers (prostate, colon, breast), infectious diseases (viral, tuberculosis), and autoimmune diseases, such as multiple sclerosis and Hashimoto's thyroiditis...
2017: Global Pediatric Health
https://www.readbyqxmd.com/read/28228781/denosumab-is-really-effective-in-the-treatment-of-osteoporosis-secondary-to-hypogonadism-in-prostate-carcinoma-patients-a-prospective-randomized-multicenter-international-study
#2
Carlo Doria, Paolo Tranquilli Leali, Federico Solla, Gianluca Maestretti, Massimo Balsano, Robero Mario Scarpa
INTRODUCTION: Osteoporosis is a complication of androgen deprivation therapy (ADT) in men with prostate carcinoma. The best defense against osteoporosis in prostate cancer is to identify patients with a high risk for fracture during the first clinical visit, select an effective anti-osteoporosis agent, and advise the patient to change his lifestyle and diet to prevent further bone loss. New agents include denosumab, a human monoclonal antibody that inhibits the RANK ligand (RANKL). RANKL promotes the formation, activity, and survival of osteoclasts and, thus, supports the breakdown of bone...
September 2016: Clinical Cases in Mineral and Bone Metabolism
https://www.readbyqxmd.com/read/28225445/adjuvant-radiotherapy-versus-wait-and-see-strategy-for-pathologic-t3-or-margin-positive-prostate-cancer-a-meta-analysis
#3
M Parvez Shaikh, Fiori Alite, Meng-Jia Wu, Abhishek A Solanki, Matthew M Harkenrider
OBJECTIVE: To conduct a meta-analysis of the randomized controlled trials (RCTs) comparing adjuvant radiotherapy (ART) to wait-and-see (WS) strategy in pathologic T3 or margin-positive prostate cancer. METHODS: A comprehensive EMBASE, MEDLINE, http://www.clinicaltrails.gov, and Cochrane Library search for RCTs of ART versus WS was done. Results were synthesized for metastasis-free, biochemical progression-free, clinical progression-free, hormone-free, and overall survival as well as gastrointestinal (GI) and genitourinary (GU) toxicities...
February 20, 2017: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28224276/preparedness-and-cancer-related-symptom-management-among-cancer-survivors-in-the-first-year-post-treatment
#4
Corinne R Leach, Alyssa N Troeschel, Dawn Wiatrek, Annette L Stanton, Michael Diefenbach, Kevin D Stein, Katherine Sharpe, Kenneth Portier
BACKGROUND: Many cancer survivors feel unprepared for the physical and psychosocial challenges that accompany the post-treatment care transition (i.e., re-entry phase), including management of cancer-related symptoms. Few studies have investigated personal and contextual factors associated with the extent of preparedness for re-entry or how they are related to cancer-related symptom management. PURPOSE: Data from the American Cancer Society's Cancer Survivor Transition Study examined (1) characteristics of breast, prostate, and colorectal cancer survivors (n = 1188) within the first year of completing treatment who are most and least prepared for re-entry; and (2) how preparedness level and other characteristics are related to cancer-related symptom management...
February 21, 2017: Annals of Behavioral Medicine: a Publication of the Society of Behavioral Medicine
https://www.readbyqxmd.com/read/28224113/intensity-modulated-radiation-therapy-with-stereotactic-body-radiation-therapy-boost-for-unfavorable-prostate-cancer-a-report-on-3-year-toxicity
#5
Ima Paydar, Abigail Pepin, Robyn A Cyr, Joseph King, Thomas M Yung, Elizabeth G Bullock, Siyuan Lei, Andrew Satinsky, K William Harter, Simeng Suy, Anatoly Dritschilo, John H Lynch, Thomas P Kole, Sean P Collins
BACKGROUND: Recent data suggest that intensity-modulated radiation therapy (IMRT) plus brachytherapy boost for unfavorable prostate cancer provides improved biochemical relapse-free survival over IMRT alone. Stereotactic body radiation therapy (SBRT) may be a less invasive alternative to brachytherapy boost. Here, we report the 3-year gastrointestinal (GI) and genitourinary (GU) toxicities of IMRT plus SBRT boost. MATERIALS AND METHODS: Between March 2008 and September 2012, patients with prostate cancer were treated with robotic SBRT (19...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/28224100/early-infant-male-circumcision-systematic-review-risk-benefit-analysis-and-progress-in-policy
#6
Brian J Morris, Sean E Kennedy, Alex D Wodak, Adrian Mindel, David Golovsky, Leslie Schrieber, Eugenie R Lumbers, David J Handelsman, John B Ziegler
AIM: To determine whether recent evidence-based United States policies on male circumcision (MC) apply to comparable Anglophone countries, Australia and New Zealand. METHODS: Articles in 2005 through 2015 were retrieved from PubMed using the keyword "circumcision" together with 36 relevant subtopics. A further PubMed search was performed for articles published in 2016. Searches of the EMBASE and Cochrane databases did not yield additional citable articles. Articles were assessed for quality and those rated 2+ and above according to the Scottish Intercollegiate Grading System were studied further...
February 8, 2017: World Journal of Clinical Pediatrics
https://www.readbyqxmd.com/read/28222995/acute-and-late-toxicity-in-high-risk-prostate-cancer-patients-treated-with-androgen-suppression-and-hypofractionated-pelvic-radiation-therapy
#7
Sergio Faria, Russel Ruo, Fabio Cury, Marie Duclos, Luis Souhami
PURPOSE: To report acute and late toxicity rates in patients with high-risk prostate cancer treated with androgen deprivation therapy (ADT) and moderate hypofractionated radiation therapy (HypoRT) to the prostate and nodal areas. METHODS AND MATERIALS: Patients with localized, high-risk prostate cancer were treated with a HypoRT regimen of 60 Gy in 20 fractions (4 weeks) to the prostate volume while the nodal areas received 44 Gy in the same 20 fractions delivered with intensity modulated RT with a simultaneous integrated boost technique...
January 20, 2017: Practical Radiation Oncology
https://www.readbyqxmd.com/read/28222973/nationwide-multi-institutional-retrospective-analysis-of-high-dose-rate-brachytherapy-combined-with-external-beam-radiotherapy-for-localized-prostate-cancer-an-asian-prostate-hdr-bt-consortium
#8
Hiromichi Ishiyama, Nobuhiko Kamitani, Hidemasa Kawamura, Shingo Kato, Manabu Aoki, Shinji Kariya, Taisei Matsumura, Motoki Kaidu, Ken Yoshida, Yaichiro Hashimoto, Yasutaka Noda, Keith H C Lim, Takatsugu Kawase, Takeo Takahashi, Koji Inaba, Motoyasu Kumano, Nobuhiko Yoshikawa, Yasuo Yoshioka, Katsumasa Nakamura, Junichi Hiratsuka, Jun Itami, Kazushige Hayakawa
PURPOSE: To report outcomes and risk factors of high-dose-rate (HDR) brachytherapy combined with external beam radiotherapy with or without androgen deprivation therapy (ADT) in prostate cancer patients. MATERIALS AND METHODS: This multi-institutional retrospective analysis comprised 3424 patients with localized prostate cancer at 16 Asian hospitals. One-thirds (27.7%) of patients received only neoadjuvant ADT, whereas almost half (49.5%) of patients received both neoadjuvant and adjuvant ADT...
February 17, 2017: Brachytherapy
https://www.readbyqxmd.com/read/28222931/novel-definitions-of-low-risk-and-high-risk-prostate-cancer-implications-for-the-european-randomized-study-of-screening-for-prostate-cancer-risk-assessment-tool
#9
EDITORIAL
Deepak K Pruthi, Donna P Ankerst, Michael A Liss
No abstract text is available yet for this article.
February 17, 2017: European Urology
https://www.readbyqxmd.com/read/28221895/use-of-evidence-based-prostate-cancer-imaging-in-a-nongovernmental-integrated-health-care-system
#10
Ramzi G Salloum, Maureen O'Keeffe-Rosetti, Debra P Ritzwoller, Mark C Hornbrook, Jennifer Elston Lafata, Matthew E Nielsen
PURPOSE: The overuse of imaging, particularly for staging of low-risk prostate cancer, is well documented and widespread. The existing literature, which focuses on the elderly in fee-for-service settings, points to financial incentives as a driver of overuse and may not identify factors relevant to policy solutions within integrated health care systems, where physicians are salaried. METHODS: Imaging rates were analyzed among men with incident prostate cancer diagnosed between 2004 and 2011 within the Colorado and Northwest regions of Kaiser Permanente...
February 21, 2017: Journal of Oncology Practice
https://www.readbyqxmd.com/read/28221219/improving-the-evaluation-and-diagnosis-of-clinically-significant-prostate-cancer-in-2017
#11
Sigrid V Carlsson, Monique J Roobol
PURPOSE OF REVIEW: To provide an overview of the current state of the evidence and highlight recent advances in the evaluation and diagnosis of clinically significant prostate cancer, focusing on biomarkers, risk calculators and multiparametric MRI (mpMRI). RECENT FINDINGS: In 2017 there are numerous options to improve early detection as compared to a purely prostate-specific antigen (PSA)-based approach. All have strengths and drawbacks. In addition to repeating the PSA and performing clinical work-up (digital rectal examination and estimation of prostate volume), additional tests investigated in the initial biopsy setting are: %free PSA, Prostate Health Index, 4-kallikrein score, SelectMDx, and Michigan Prostate Score and in the repeat setting: %free PSA, Prostate Health Index, 4-kallikrein score, Prostate Cancer Antigen 3, and ConfirmMDx...
February 17, 2017: Current Opinion in Urology
https://www.readbyqxmd.com/read/28220805/meta-analysis-of-metabolic-syndrome-and-prostate-cancer
#12
REVIEW
M Gacci, G I Russo, C De Nunzio, A Sebastianelli, M Salvi, L Vignozzi, A Tubaro, G Morgia, S Serni
BACKGROUND: Metabolic syndrome (MetS) and prostate cancer (PCa) are highly prevalent conditions worldwide. Current evidence suggests the emerging hypothesis that MetS could play a role in the development and progression of several neoplasms. The aims of this study are to evaluate the impact of MetS and MetS factors on PCa incidence, on the risk of high-grade PCa and to analyze the role of MetS and single MetS components on the development of aggressive PCa features. METHODS: A systematic literature search and analysis on PubMed, EMBASE, Cochrane and Academic One File databases until September 2015 was performed by 2 independent reviewers to evaluate the associations between MetS and PCa incidence, and between MetS and high-grade PCa incidence (bioptical Gleason Score⩾8, Prognostic Group 4-5 according to the novel prostate cancer grading system)...
February 21, 2017: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/28220802/the-prostate-cancer-prevention-trial-risk-calculator-2-0-performs-equally-for-standard-biopsy-and-mri-us-fusion-guided-biopsy
#13
M Maruf, M Fascelli, A K George, M M Siddiqui, M Kongnyuy, J M DiBianco, A Muthigi, S Valayil, A Sidana, T P Frye, A Kilchevsky, P L Choyke, B Turkbey, B J Wood, P A Pinto
BACKGROUND: The Prostate Cancer Prevention Trial Risk Calculator 2.0 (PCPTRC) is a widely used risk-based calculator used to assess a man's risk of prostate cancer (PCa) before biopsy. This risk calculator was created from data of a patient cohort undergoing a 6-core sextant biopsy, and subsequently validated in men undergoing 12-core systematic biopsy (SBx). The accuracy of the PCPTRC has not been studied in patients undergoing magnetic resonance imaging/ultrasound (MRI/US) fusion-guided biopsy (FBx)...
February 21, 2017: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/28217016/prostate-specific-antigen-as-a-risk-factor-for-skeletal-metastasis-in-native-ethnic-african-men-with-prostate-cancer-a-case-control-study
#14
Ayman M Qureshi, Khalid Makhdomi, William Stones
Prostate cancer is the most common noncutaneous cancer in males. Men of African origin are at a significantly higher risk as reflected in the higher incidence and mortality rates in this racial group. Metastases incidence increases parallel to serum levels of prostate-specific antigen (PSA), contributing significantly to morbidity and mortality. Staging of the disease involves bone scans, which are sensitive in detecting skeletal metastases. Suggestions that these scans may be omitted in some situations in patients with low prostate specific antigen levels have drawn attention to the matter...
January 2017: World Journal of Nuclear Medicine
https://www.readbyqxmd.com/read/28216329/oncological-and-functional-outcomes-after-radical-prostatectomy-for-high-or-very-high-risk-prostate-cancer-european-validation-of-the-current-nccn-guideline
#15
Raisa S Pompe, Pierre I Karakiewicz, Zhe Tian, Philipp Mandel, Thomas Steuber, Thorsten Schlomm, Georg Salomon, Markus Graefen, Hartwig Huland, Derya Tilki
PURPOSE: To validate the current NCCN-classification of very high-risk (VHR) patients and compare the pathological, functional and oncological outcomes between surgically treated high- (HR) and VHR patients. MATERIALS & METHODS: We retrospectively analyzed 4041 patients stratified into high- or VHR who underwent RP between 1992-2016. Kaplan-Meier as well as multivariable logistic and Cox regression analyses compared outcomes between the two groups. RESULTS: After RP, the rate of adverse pathological features was higher in 1369 VHR vs...
February 16, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28216328/outcomes-of-prostate-cancer-screening-by-5-alpha-reductase-inhibitor-usage
#16
Teemu J Murtola, Anniina Virkku, Kirsi Talala, Ulf-Håkan Stenman, Kimmo Taari, Teuvo Lj Tammela, Anssi Auvinen
PURPOSE: Prostate cancer (PCa) screening with prostate-specific antigen (PSA) reduces PCa mortality, but leads to overdiagnosis of indolent PCa. Use of 5-alpha reductase inhibitors (5-ARIs) lowers PSA and in theory could affect performance of PSA-based screening. We evaluated outcomes of PCa screening among 5-ARI users. MATERIALS AND METHODS: The study was performed within the Finnish Randomized Study of Screening for Prostate Cancer. Of 80,454 men, 31,866 were randomized to be screened at four-year intervals during 1996-2004...
February 16, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28215847/prostate-cancer-screening-in-men-aged-50-to-69-years-sthlm3-a-prospective-population-based-diagnostic-study-gr%C3%A3-nberg-h-adolfsson-j-aly-m-nordstr%C3%A3-m-t-wiklund-p-brandberg-y-thompson-j-wiklund-f-lindberg-j-clements-m-egevad-l-eklund-m-lancet-oncol-2015-dec-16
#17
Eggener Scott, J Adolfsson, M Aly, T Nordström, P Wiklund, Y Brandberg, J Thompson, F Wiklund, J Lindberg, M Clements, L Egevad, M Eklund
BACKGROUND: The prostate-specific antigen (PSA) test is used to screen for prostate cancer but has a high false-positive rate that translates into unnecessary prostate biopsies and overdiagnosis of low-risk prostate cancers. We aimed to develop and validate a model to identify high-risk prostate cancer (with a Gleason score of at least 7) with better test characteristics than that provided by PSA screening alone. METHODS: The Stockholm 3 (STHLM3) study is a prospective, population-based, paired, screen-positive, diagnostic study of men without prostate cancer aged 50 to 69 years randomly invited by date of birth from the Swedish Population Register kept by the Swedish Tax Agency...
March 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28214281/patient-characterization-and-usage-trends-of-proton-beam-therapy-for-localized-prostate-cancer-in-the-united-states-a-study-of-the-national-cancer-database
#18
Arya Amini, David Raben, E David Crawford, Thomas W Flaig, Elizabeth R Kessler, Elaine T Lam, Paul Maroni, Thomas J Pugh
PURPOSE: To evaluate usage trends and identify factors associated with proton beam therapy (PBT) compared to alternative forms of external beam radiation therapy (RT) (EBRT) for localized prostate cancer. PATIENTS AND METHODS: The National Cancer Database was queried for men with localized (N0, M0) prostate cancer diagnosed between 2004 and 2013, treated with EBRT, with available data on EBRT modality (photon vs. PBT). Binary multiple logistic regression identified variables associated with EBRT modality...
February 14, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28213801/efficacy-of-a-neoadjuvant-gonadotropin-releasing-hormone-antagonist-plus-low-dose-estramustine-phosphate-in-high-risk-prostate-cancer-a-single-center-study
#19
Kazuhisa Hagiwara, Takuya Koie, Chikara Ohyama, Hayato Yamamoto, Atsushi Imai, Shingo Hatakeyama, Takahiro Yoneyama, Yasuhiro Hashimoto, Yuki Tobisawa, Tohru Yoneyama
PURPOSE: The optimal treatment for high-risk prostate cancer (Pca) remains to be established. We previously reported favorable biochemical recurrence-free survival (BRFS) for high-risk Pca patients treated with neoadjuvant therapy comprising a luteinizing hormone-releasing hormone agonist plus low-dose estramustine (LHRH + EMP) prior to radical prostatectomy (RP). In the present study, we evaluated the efficacy of neoadjuvant therapy comprising a gonadotropin-releasing hormone antagonist plus low-dose estramustine phosphate (GnRH + EMP) in patients with high-risk Pca...
February 17, 2017: International Urology and Nephrology
https://www.readbyqxmd.com/read/28213657/the-roles-of-uvb-and-vitamin-d-in-reducing-risk-of-cancer-incidence-and-mortality-a-review-of-the-epidemiology-clinical-trials-and-mechanisms
#20
REVIEW
Meis Moukayed, William B Grant
Global cancer incidence and mortality rates are high and increasing. Thus, it is imperative to find novel solutions to preventing cancer incidence and treating it at an affordable yet efficacious manner. The solar UVB-vitamin D-cancer hypothesis was first proposed in 1980 based on a geographical ecological study. Since then, numerous ecological and observational studies as well as studies of mechanisms have provided support for the hypothesis. However, observational studies have not provided consistent support, in part due to using a single blood draw from any season to use for serum 25-hydroxyvitamin D [25(OH)D] concentration in prospective studies with long follow-up times...
February 17, 2017: Reviews in Endocrine & Metabolic Disorders
keyword
keyword
69231
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"